898 results on '"Mehta, Jayesh"'
Search Results
2. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
3. An Illustrative Case of Daratumumab-associated Leukoencephalopathy: A Rare but Important Complication of Anti-CD38 Therapy in Multiple Myeloma Patients (P6-5.021)
4. 215.8: Long-term Follow-up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients
5. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
6. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter
7. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma
8. Evaluation of a Perceived Cluster of Plasma Cell Dyscrasias Among Workers at a Natural Gas Company — Illinois, 2014
9. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
10. Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD
11. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
12. Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
13. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
14. Single Institution Review of Anakinra for the Management of Icans in CAR T-Cell Therapy
15. Is Language a Barrier to Assessment of Neurotoxicity Associated with CAR T-Cell Therapy?
16. Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
17. Infections in Patients with Hematologic Malignancies
18. Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis
19. Cytokines in Hematopoietic Stem Cell Transplantation
20. Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients
21. Dose-intense etoposide–cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia
22. Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia
23. Changing Epidemiology of Clostridium difficile–Associated Disease during Stem Cell Transplantation
24. Questioning the Role of a Neutropenic Diet following Hematopoetic Stem Cell Transplantation
25. Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project
26. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia
27. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
28. How I treat elderly patients with myeloma
29. Myeloid Sarcoma Reveals a Unique Tumor Micro-Environment and Differential Prognosis Based on Transplant Status and Type of Treatment Received
30. Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial
31. Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question
32. Engraftment Syndrome Incidence after Immune Checkpoint Inhibitor Therapy in Pts with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Single Institutional Review
33. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
34. Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
35. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
36. Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
37. Lenalidomide in Myeloma
38. Anti-Infective Prophylaxis, Immunization and Prevention of Recurrent Infectious Complications in Long-Term Survivors
39. Hematopoietic growth factors pass through the blood–brain barrier in intact rats
40. Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
41. Treatment of relapsed and refractory multiple myeloma
42. Novel Therapies in Multiple Myeloma
43. Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique
44. Thalidomide in Cancer: Potential Uses and Limitations
45. Reimmunization after stem cell transplantation
46. List of contributors
47. 467 - Is Language a Barrier to Assessment of Neurotoxicity Associated with CAR T-Cell Therapy?
48. 253 - Single Institution Review of Anakinra for the Management of Icans in CAR T-Cell Therapy
49. PET–CT in lung cancer: data discrepancies
50. Induction therapy and outcome in acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.